Launch week offerEnds in00h00m00s

annual Promonthly Pro

Konstantinos Floros

Research Assistant Professor

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Cell Biology Cell Biology professors in United States

About

Dr. Konstantinos Floros is a Research Assistant Professor at Virginia Commonwealth University (VCU) in the United States. His research focuses on cancer biology, particularly in exploring therapeutic targets in triple-negative breast cancer and neuroblastoma. With recent publications investigating the roles of ubiquitin-like modifiers and metabolic vulnerabilities in cancer cells, Dr. Floros contributes significantly to understanding acquired resistance to targeted therapies.

Articles (9)

Year:

2026

Year:

2025

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Alexandros Dimopoulos

Assitant Professor

Harokopio University

GREECE

View details

Anthony Faber

Professor

Virginia Commonwealth University

UNITED STATES

View details

Renfeng Li

Assocaite Professor

University of Pittsburgh

UNITED STATES

View details

Mikhail Dozmorov

Associate professor

Virginia Commonwealth University

UNITED STATES

View details

Senthil K. Radhakrishnan

Virginia Commonwealth University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Konstantinos Floros

Research Interests

Make your next move.

Explore related searches

About

Articles (9)

Beyond blacklists: a critical assessment of exclusion set generation strategies and alternative approaches

Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma

Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Collaborators (5)

Alexandros Dimopoulos

Anthony Faber

Renfeng Li

Mikhail Dozmorov

Senthil K. Radhakrishnan

Make your next move.